a biosimilar version of the insulin blockbuster Lantus launched today in the US. Basaglar will also undercut Sanofi’s longer lasting version, Toujeo, and is likely to win a large share of the ...

Sanofi's rivals in the insulin field are nipping at its heels – Lantus sales dipped 5 per cent in the first half of 2015, and analysts don't expect Toujeo to make up for its decline.